重组鼠白细胞介素-36β 153a.a.蛋白 rMuIL-36β

重组鼠白细胞介素-36β，153a.a.蛋白

Synonyms	FIL1 eta, IL-1 eta, IL-1F8, IL-1H2
Species	Murine
Accession	Q9D6Z6
GeneID	69677
Source	重组鼠白细胞介素-36β，153a.a.蛋白Escherichia coli.
Molecular Weight	Approximately 17.4 kDa, a single non-glycosylated polypeptide chain containing 153 amino acids.
Quantity	2µg/10µg/1000µg
AA Sequence	SSQSPRNYRV HDSQQMVWVL TGNTLTAVPA SNNVKPVILS LIACRDTEFQ DVKKGNLVFL GIKNRNLCFC CVEMEGKPTL QLKEVDIMNL YKERKAQKAF LFYHGIEGST SVFQSVLYPG WFIATSSIER QTIILTHQRG KLVNTNFYIE SEK
Purity	重组鼠白细胞介素-36β，153a.a.蛋白> 97 % by SDS-PAGE and HPLC analyses.
Biological Activity	Fully biologically active when compared to standard. The ED₅₀ as determined by inducing IL-6 secretion in murine NIH/3T3 cells is less than 10 ng/ml, corresponding to a specific activity of > 1.0 × 10⁵ IU/mg.
Physical Appearance	Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation	Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4, 5% trehalose.
Endotoxin	重组鼠白细胞介素-36β，153a.a.蛋白Less than 1 EU/µg of rMuIL-36β, 153a.a. as determined by LAL method.
Reconstitution	We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Storage	This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles.
重组鼠白细胞介素-36β，153a.a.蛋白
SDS-PAGE
Reference	1. Nicklin MJ, Barton JL, Nguyen M, et al. 2002. Genomics. 79:718-25. 2. Dinarello C, Arend W, Sims J, et al. 2010. Nat Immunol. 11:973. 3. Magne D, Palmer G, Barton JL, et al. 2006. Arthritis Res Ther. 8:R80. 4. van Asseldonk EJ, Stienstra R, Koenen TB, et al. 2010. Obesity (Silver Spring). 18:2234-6. 5. Johnston A, Xing X, Guzman AM, et al. 2011. J Immunol. 186:2613-22.
Background	Interleukin-36 is a pro-inflammatory cytokine which plays an important role in the pathophysiology of several diseases. IL-36α, IL-36β, and IL-36γ (formerly IL-1F6, IL-1F8, and IL-1F9) are IL-1 family members that signal through the IL-1 receptor family members IL-1Rrp2 (IL-1RL2) and IL-1RAcP. IL-36 beta is reported to be expressed at higher levels in psoriatic plaques than in symptomless psoriatic skin or healthy control skin and it can stimulate production of interleukin-6 and interleukin-8 in synovial fibrobasts, articular chondrocytes and mature adipocytes. IL-36 beta has two isoforms. IL-36β2 contains one potential N-linked glycosylation site in its C-terminus, while IL -36β isoform 1 lacks potential N-linked glycosylation sites and four of the conserved β-strands. Within the IL-1 family, IL-36β/IL-1F8 shares 30 %, 32 %, 37 %, 46 %, 34 %, 45 % and 28 % a.a. sequence identity with IL-1 ra, IL-1β, IL-36Ra/IL-1F5, IL-36α/IL-1F6, IL-37/IL-1F7, IL-36γ/IL-1F9 and IL-1F10, respectively.